海辰藥業(300584.SZ)2021年度扣非淨利潤預降30%-50%
格隆匯1月19日丨海辰藥業(300584.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤2.88億元-2.99億元,同比增長422.09%-441.30%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2652.13萬元–3712.98萬元,同比下降30%-50%。全年業績同比大幅增長的主要原因是:
1、報吿期內,公司投資項目主體高研歐進基金與非關聯第三方PAGAC IIINemo Holding (HK) Limited簽訂了關於高研歐進生物的股權轉讓協議。根據《企業會計準則》有關規定,公司以此交易價格為客觀依據,對該金融資產期末金額進行公允價值估值確認。經測算,扣除相關税費後,本金融資產公允價值收益可獲得淨利潤約26021.42萬元。
2、報吿期內,受地區帶量採購、臨牀使用限制等因素的影響,公司產品銷量有一定幅度的下降,公司營業收入和扣非後淨利潤隨之下降;公司預計非經常性損益對淨利潤的影響金額約26183.14萬元,影響較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.